

Emerging Trends in Amyl Nitrite Use

Findings from Drug Trends

Dr Amy Peacock, National Drug and Alcohol Research Centre, UNSW, Sydney
Therapeutic Goods Administration Alkyl Nitrites Public Meeting
Kirby Institute, UNSW Sydney

Funded by the Australian Government under the Drug and Alcohol Program



Acknowledgements


Funding

- Australian Government Department of Health: for funding provided under the Drug and Alcohol Program
- **Drug Trends Team**
- **National Drug and Alcohol Research Centre**
- **Burnet Institute (VIC)**
- **University of Tasmania**
- **National Drug Research Institute (WA)**
- **University of Queensland (QLD)**
- **Northern Territory Department of Health (NT)**

Other Acknowledgements:

- Participants: for the time they provide in completing the interview
- Data custodians: for the timely provision of data and input on analysis and interpretation
- Stakeholders: for engagement with and input on Drug Trends

History of Drug Trends



Australian Government
Department of Health
Therapeutic Goods Administration



To establish, maintain, and continuously improve monitoring of drug trends across Australia

National Monitoring with Secondary Data

Mortality Data
Drug-induced deaths from NCIS and ABS

Hospitalisation Data
Drug-induced hospitalisations from NHMD

Other Sources
NDSHS, AODTS-NMDS etc

Single source regular reports

Jurisdictional Monitoring with Secondary Data

Various data sources assessing drug use and harms at the population-level (e.g., hospital separations, emergency department presentations) and subpopulation level (e.g., NSP visits)

Single source regular reports

Sentinel Sample Monitoring

Illicit Drug Reporting System (IDRS) Ecstasy and Related Drug Reporting System (EDRS)
Annual interviews with people who inject drugs (IDRS) and who use stimulants (EDRS) in each capital city

Single source regular reports

Online Monitoring

Darknet Market Data
Scraping listings on darknet drug markets

Single source regular reports

Input from CIs, national stakeholders, and jurisdiction stakeholders to inform priority research questions and interrogation of data

Analytical reports using triangulated data



Demographic characteristics of the EDRS sample, 2018

EDRS eligibility criteria:

Be at least 16 years of age


Have used ecstasy or other stimulants at least six times in the 6 months preceding interview

Have been a resident of the capital city for the past 12 months


National EDRS sample, 2018	N=799
Median age (years, IQR)	21 (19-24)
% Male	59
% Aboriginal and/or Torres Strait Islander	6
% Heterosexual	84
% Gay male or male bisexual	6
Mean years of school education	12
Employed full-time	22
Students	18
Renting house/flat	44
Parents'/family home	48




Amyl nitrite use last six months, national, 2003-2018




Amyl nitrite use last six months, by jurisdiction, 2018




Amyl nitrite use last six months, ACT, NSW, SA & NT, 2003-2018



Amyl nitrite use last six months, WA, TAS, QLD & VIC, 2003-2018




Recent drug use and 'drug of choice', national, 2018



Australian Government
Department of Health
Therapeutic Goods Administration



Median days of amyl nitrite use, national, 2003-2018



Note. Participants are asked number of days used in past six months (maximum = 180 days)



Australian Government
Department of Health
Therapeutic Goods Administration



Characteristics of consumers vs non-consumers, 2018

Data redacted

*Note. * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$*



Australian Government
Department of Health
Therapeutic Goods Administration



UNSW
SYDNEY



Kirby Institute



afao
AUSTRALIAN FEDERATION
OF AIDS ORGANISATIONS
LIFE IS WORTH LIVING WITH HIV



NDARC
National Drug &
Alcohol Research Centre
The Difference is Research

Characteristics of consumers vs non-consumers, 2018

Data redacted

Note. * $p < 0.050$; ** $p < 0.010$; *** $p < 0.001$



Australian Government
Department of Health
Therapeutic Goods Administration



Characteristics of consumers vs non-consumers, 2018

Data redacted



Australian Government
Department of Health
Therapeutic Goods Administration



UNSW
SYDNEY



Kirby Institute



AUSTRALIAN FEDERATION
OF AIDS ORGANISATIONS
Let's work together to end HIV



National Drug &
Alcohol Research Centre

The Difference is Research

Proportion of men who reported recent amyl nitrite use, by sexual identity, 2015-2018

Data redacted



Australian Government
Department of Health
Therapeutic Goods Administration



UNSW
SYDNEY



Kirby Institute



AUSTRALIAN FEDERATION
OF AIDS ORGANISATIONS
Let's work together to end HIV



National Drug &
Alcohol Research Centre

The Difference is Research

Bingeing behaviours and non-fatal overdose, 2018

Data redacted



Australian Government
Department of Health
Therapeutic Goods Administration



UNSW
SYDNEY



Kirby Institute



AUSTRALIAN FEDERATION
OF AIDS ORGANISATIONS
Unit 10, 100 Victoria Road, Sydney NSW 1570



The University of Queensland

Summary

1. Amyl nitrite is uncommon (and use infrequent) relative to other drug use among people who regularly use ecstasy and other illicit stimulants.
2. People who report amyl nitrite use are typically more likely to endorse use of a range of illicit drugs relative to those who do not report use.
3. Acute health harms of amyl nitrite use were not assessed. Yet, indicators suggest that amyl nitrite use is infrequently consumed in instances of overdose and other problematic drug use behaviours (e.g., binge use).

